Objective: Rheumatoid arthritis (RA) is a systemic and autoimmune disorder whose primary characteristic is the chronic inflammation of joints. The objective of this study was to evaluate whether there was an association between nuclear factor kappa beta1/IKK epsilon (NF-κB1/IKKε) gene expression and clinical activity in RA.
(NCT02689115); written informed consent was obtained from all subjects.
Patients
The key inclusion criteria were patients with RA who met the criteria established by the American College of Rheumatology (ACR). 10 Two groups were conformed based on the Disease Activity Score 28 (DAS28), 11 1) with clinical activity (DAS28 > 3.6) and 2) with clinical remission (DAS28 < 2.4). Key exclusion criteria included patients with any other inflammatory or autoimmune disease, and patients with infections.
Sample Size
The sample calculation was based on the following formula: Accepting an alpha risk of 0.05 and a beta risk of 0.2 in a 2-sided test, 28 subjects per group were necessary to recognize a statistically significant difference greater than or equal to 3 relative expression units (fold changes). The common standard deviation was assumed to be 4, based on a previous publication 12 in which the same genes were used.
Anthropometric Measurements
Weight ( 
Lymphocyte Extraction
Lymphocytes from peripheral blood were extracted using the ACK Lysing Buffer (Life Technologies, Grand Island, NY) kit. Briefly, a venous blood sample (2.5 mL) in an EDTA tube (BD Vacutainer; BD, Franklin Lakes, NJ) was centrifuged at 3500 rpm during 5-8 minutes. The resulting buffy coat was extracted and placed in an Eppendorf tube; 1 mL of ACK Lysing Buffer was added and carefully resuspended. Once again, the suspension was centrifuged at 1900 rcf during 5-8 minutes, and the supernatant was discarded. This latter step was repeated until the leukocyte package (4000-10,000 cells) was completely white (approximately 10-15 mg). Finally, 100 uL of ACK Lysing Buffer was added, and this was frozen at -70ºC for later use.
Gene Expression
From the leukocyte lysate, a messenger RNA (mRNA) extraction was performed using the Magna Pure LC RNA Isolation Kit III (Roche) in the Magna Pure LC 2.0 Instrument. The A260-280-nm absorbance ratio was >1.8 (quality), and total RNA concentration (ng/uL) was calculated by determining absorbance at 260 nm with a NanoPhotometer (Implen GmbH, Germany).
Subsequently, the complementary DNA (cDNA) was synthesized with the Transcriptor High Fidelity cDNA Synthesis Kit (Roche Applied Science); 100 ng of RNA in a final volume of 15 uL was used per reaction. The quantitative polymerase chain reaction (qPCR) was performed utilizing a 7500 Fast Real-Time PCR System (Applied Biosystems, Applera UK, Cheshire, UK), mixing TaqMan Universal PCR Master Mix and the specific probes (Applied Biosystems) for each gene, including NF-κB1 (Hs00765730-m1), IKKε (Hs01063858-m1), and 18S (Hs99999901-s1); the last was used as a control gene. The conditions for the qPCR are depicted in Table 1 .
According to the CT obtained from the 2 different groups, relative expression was calculated by the fold change in NF KB, and IKK was normalized against the constitutively expressed reference genes, then compared to the untreated controls (calibration sample) as follows: 2 − ΔΔCT, where ΔΔCT = (CT-target − CT-reference) treated-sample − (CT-target − CT-reference) calibrator-sample. Calibrator -sample refers to the expression level (1×) of the target gene normalized to the constitutive gene. The calibrator was chosen from the group with clinical activity and given a relative expression value of 1.
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Statistical Analysis
The correlation among NF-κB1, IKKε and DAS28 was performed through the Spearman test. The multivariate lineal general model was used to evaluate the drug effect on the NF-κB1 and IKKε RU and DAS28 punctuation. For the 2 genes, ROC curves with the area under the curve (AUC) and 95% confidence interval (CI) were constructed for the event "clinical activity." Finally we evaluated the best curve model for both genes and the clinical activity. Any P value ≤ .05 was considered significant. All tests were performed with the SPSS v 15 software (SPSS, Chicago, IL).
Results
From a total of 680 patients attended in the aforementioned period, 60 patients were included in the study, mean age 52 ± 11.62 years, 30 with clinical activity (28 women and 2 men) and 30 in clinical remission (26 women and 4 men). From the first group, 6 patients had high activity (DAS28 >5.1) and 24 moderate activity (DAS28 <3.2). Table 3 the CT values of each sample and gene are displayed. Whilst the anthropometric measurements did not demonstrate significant differences, the converse occurred in the gene expression of both NF-κB1 (P ≤ .001) and IKKε (P = .008). In contrast, while the NF-κB1 expression was detected in all cases, IKKε expression was confirmed in 16 patients with clinical activity and only in three with clinical remission. The intragroup analysis between moderate and high clinical activity using the Mann-Whitney U test did not show any significant difference for the 2 target genes.
The Kolmogorov test showed a non-Gaussian distribution for the 2 tested genes. Therefore, the Spearman correlation test was performed with the previous 2 genes and the DAS28 scale punctuation, resulting in a significant positive correlation between NF-κB1 and DAS 28 (r 2 = .495, P ≤ .001). Notoriously, 25 patients (83.33%) in the group of clinical activity and 26 (26.66%) in the group of clinical remission were prescribed nonsteroidal anti-inflammatory drugs (NSAIDs). In both groups, the most common combination of drugs was a disease-modifying antirheumatic drug plus an NSAID. The multivariate lineal general model showed that the use of NSAIDs influenced the NF-κB1 (P = .046) and IKKε (P = .005) relative expression. Moreover, when comparing the expression of both genes, contrasting the use of the drug family, there was a significant difference in IKKε when the patients were in NSAIDs treatment (P = .003; Table 4 ).
Finally, through the ROC curves, including the missing values, the AUC (95% CI) for NF-κB1 and IKKε were 0.827 (0.717-937), P ≤ .001; and 0.550 (400-700), P = .506, respectively ( Figure 1 ).
Taking into account the effect of NSAIDs, we proceeded to evaluate the best curve estimation for our dataset, leading to the logarithmic and potency models as those that fit better with our data (P ≤ .001).
It is worth noting that 11 patients from the group of clinical activity suffered from at least 1 episode of infection, while in the group of clinical remission, only 6 had this kind of complication. The type of drugs that the patients were taking is depicted in Table 5 .
Discussion
It is important to specify that, among the group of patients without clinical activity, the majority recorded no amplification in the IKKε transcript, in contrast with patients with active RA, in whom important variations in the relative expression were observed.
Different studies have linked NF-kB overexpression with inflammatory and autoimmune processes in diseases such as RA, systemic lupus erythematosus (SLE), and psoriasis. [14] [15] [16] [17] However, there is no clear information on whether there is a link between clinical activity and NF-κB1 gene expression adjusting the results to the pharmacological treatment.
In this study, we show that there does exist a significant difference between the degree of NF-κB1 expression of patients with clinical disease activity vs those with clinical remission. Thus, it is possible to suggest that these pathways may be therapeutic targets in RA, in that there is higher expression in patients with clinical activity compared with patients with clinical remission. This especially applies if it is considered as background that the NF-κB1 family comprises transcription factors that stimulate the synthesis of various inflammatory cytokines involved in RA inception and development, such as IL-1, IL-6, and TNF-α. Therefore, regulating the expression of these transcripts could be a future therapeutic alternative. This is also suggested as a possible inflammatory biomarker, because the clinical activity is directly linked with the presence of the inflammatory process.
In the case of IKKε, it is noteworthy that it is a gene triggered by a severe inflammatory stimulus, and that it is expressed predominantly in the cells and tissues of the immune system; it has been described, specifically, that the primary activity of IKKε is the chronic activation of synovial inflammation in an arthritic joint; 18 thus, as expected, a significant difference was found between patients without inflammation and patients with inflammation. Consequently, it is possible to suggest that IKKε may be considered in this physiopathology, in that its expression is linked with chronic inflammation and depends on the quite severe inflammatory stimulus, 2 visible aspects in a patient with clinical activity. While further work is required to define in detail the role of IKKε in RA, it could be considered an activity indicator, because an important percentage of patients in clinical remission had undetectable levels of IKKε expression, contrary to patients with disease activity.
Our results demonstrate a clear difference in the expression of NF-κB1/IKKε in peripheral blood mononuclear cells depending on the clinical activity. Whether this finding can be extrapolated to the joint where disease occurs is something to be corroborated, but the molecular mechanism leading to erosions and periarticular and generalized osteoporosis in RA suggest so. 19 Furthermore, the damage to the joints can be modified by the antirheumatic drug group. 20 During this research, other aspects linked to the RA were also evaluated; this is the case of BMI. The literature reports that obesity is considered at present a low-grade inflammatory pathology whose consequence is the increase of the plasmatic levels of proinflammatory cytokines such as TNF-α and acute-phase reactants, such as the C-reactive protein (CRP). 21, 22 Obesity is also considered a risk factor for RA.
This has been reported in studies in which it was observed that with regard to the levels of leptin and other types of adipokines that regulate different physiological functions, including the immune response, these levels are elevated in those with obesity. This represents a strong connection with obesity under diverse autoimmune conditions, such as RA, SLE, type 1 diabetes, and Hashimoto thyroiditis. 23, 24 Conversely, other authors suggest that being overweight only adds a traumatic load to the joints and that, subsequently, there exists a higher predisposition to suffer osteoarthritis, a mechanical but not a metabolic problem, and the connection with RA is not at all clear. However, in the present study, there was no difference in the degree of NF-κΒ1/IKKε gene expression among patients with normal weight, overweight, and obesity, both for the group with clinical activity and for that with clinical remission. A significant difference was not recorded in the BMI, the weight, or the height of both groups. Therefore, it is suggested that overweight and obesity constitute probable risk factors in the development of the disease because currently, obesity is considered a minor inflammatory process. Notwithstanding, this has no connection with clinical activity. In this regard, the main causes for a clinical improvement are treatment adherence, treatment response, application of attenuated-virus vaccines, and recurrent infections. The latter triggers the immune response and the production of proteins that give rise to inflammatory processes, such as TNF-α, 1 of the cytokines of major relevance in the clinical activity of patients with RA.
In addition, we chose to perform a biochemical analysis on each patient in which the glucose was considered, because some studies mention that patients with RA and active disease exhibit strong resistance to the elevation-induced insulin of TNF-α. Based on this presumption, the patients with moderate-to-high clinical activity would be expected to demonstrate higher levels of glucose than patients with clinical remission; however, the results showed that no differences in the glucose levels of both groups, although it is possible that this is due to patients undergoing treatment for RA. [27] [28] [29] Both groups were analyzed depending on the treatment, without finding any significant difference in BMI, NF-κB1 and IKKε. This was unexpected since the biological treatment is focused on suppressing TNF-α, [30] [31] [32] the primary activator in the NF-κB1 signaling pathway by its canonical or classic pathway. By contrast, IKKε belongs to an alternative pathway that is different from the already known pathways and does not depend on TNF-α to be triggered; thus, it should not be affected by the biological treatment. 33 However, the multivariate lineal general model showed that NSAIDs use influences the NF-κB1 and IKKε expression.
Importantly, this pathway appears to have cell type-specific functions, and since many different cell types are involved in the pathogenesis of RA, it is difficult to predict the net overall contribution of the non-canonical NF-κB pathway to synovial inflammation, or clinical indication, and on the other hand, as we propose with this study, this will allow the design of better therapeutic strategies for the management of this disease, including cell type-specific inhibitors or selective targeting of inhibitors to certain cell types. Some authors propose that NF-κB pathway is a promising new therapeutic target, not only in RA, but also in other immune-mediated inflammatory diseases. 34, 35 Finally, there is a latent possibility of biased results due to the infections in the group with clinical activity. As it is known, NFκB transcription factors are activated upon infection, via triggering of various sensors, like the TLRs (toll-like receptors), which are expressed on cells of the innate immune system, including macrophages, dendritic cells, and mucosal epithelial cells. 36 Surprisingly, information is scarce about RA, infections, and the activation of the NFκB/IKKε module. 37, 38 We are aware that a clear limitation of this study is that the elected genes might be difficult to quantify in an everyday medical practice, but in a second-or third-level hospital with a rheumatology service, they could help to identify patients without clinical improvement. Thus, the major strength of our study is the identification of IKKε as clearly positive in RA patients with clinical activity and its negativity in 90% of patients in clinical remission. LM
